Divestment of sepofarsen and ultevursen ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued advancement of pipeline
€129 M cash and cash equivalents as of June 30, 2023 providing runway into mid-2026
Annual General Meeting of Shareholders to be held on June 30, 2022René Beukema joins management team as Chief Corporate Development Officer and General Counsel and is nominated to Management BoardGerard Platenburg to assume Chief Scientific Officer role, with le
… 10 (LCA10). Presentation title : Proof-of-concept for RNA-editing oligonucleotide QR-110 for treatment of inherited … clinical studies Poster presentation on Axiomer ® RNA editing technology A presentation will be delivered by … computational analytics of ProQR on the Axiomer ® RNA editing technology. Poster title: Structure-based …
… with LCA10 and preclinical data for ProQR’s Axiomer ® RNA-editing technology. Abstract titles: ○ Proof-of-concept for RNA-editing oligonucleotide QR-110 for treatment of inherited … ® EONs are designed to recruit an endogenously expressed RNA editing system called ADAR, which it can direct to the …
… (SAB). In vivo proof of concept data for novel Axiomer ® RNA editing platform technology presented at the OTS meeting … of concept data for its novel and proprietary Axiomer ® RNA editing technology platform at the Oligonucleotide …
… of RNA-based therapeutics, particularly in the area of RNA editing. As an expert in the field of ADAR and A-to-I … in advancing the company’s novel and proprietary Axiomer ® RNA editing technology. The board now consists of seven …
ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022
Company plans to discuss findings from sepofarsen Illuminate trial w